Lee YI, et al. - Researchers ascertained the safety and efficacy of 0.2% topical sirolimus for the treatment of facial angiofibroma. They also compared its impacts based on age. Authors noted safety and effectiveness of 0.2% sirolimus ointment for facial angiofibromas. As per data, an early initiation of the treatment is recommended, in view of its higher efficacy in younger patients. With the fastest response to the treatment, most significant reduction was seen in the erythema among the subcategories of Facial Angiofibroma Severity Index (FASI).